Turning to costs, our G&A expenses for the first quarter of 2012 were $6.9 million compared to $5.8 million in 2011. Total cash and equivalents as of March 31, 2012 were $192.5 million compared to $227.9 million as of December 31, 2011. The decrease in cash is primarily due to the second and final payment of $27.5 million to MedImmune under our February 20, 2011 settlement agreement.
Net cash provided by operating activities in the first quarter of 2012 was $17.9 million compared with net cash used of $13.2 million in equivalent period of 2011. Net income for the first quarter of 2012 was $40.2 million or $0.29 per diluted share as compared with net income of $44.5 million in the same period of 2011 or $0.25 per diluted share.
On slide five, you could see that adjusting for the effects of certain convertible note transactions and the resulting interesting expense, non-GAAP net income for the first quarter of 2012 on a fully diluted basis was $41.8 million or $0.30 per share compared to $44.5 million or $0.25 per share in that same period of 2011.
In accordance with our regular quarterly dividend policy, we paid the first of four dividends on March 14 th to all stockholders of record as of March 7 th for a total of $21 million.You can see on slide six that, in connection with this dividend payment, the conversion price for the $1 million outstanding on our February 2015 notes is approximately $6.29 per share effective March 8, 2011. For our May 2015 notes, the conversion price is approximately $7.18 per share effective March 5, 2011. The conversion price for the new series 2012 notes is approximately $6.29 per share effective March 5, 2012. Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV